{"id":"conventional-best-asthma-therapy","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Tremor"},{"rate":"5-10","effect":"Headache"},{"rate":"1-5","effect":"Palpitations"},{"rate":"1-5","effect":"Oral candidiasis"},{"rate":"1-3","effect":"Hoarseness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Inhaled corticosteroids suppress airway inflammation by inhibiting inflammatory mediators and immune cell recruitment, while long-acting beta-2 agonists activate beta-2 adrenergic receptors on airway smooth muscle to promote bronchodilation. This combination approach addresses both the inflammatory and bronchospasm components of asthma pathophysiology. The term 'conventional best asthma therapy' refers to the standard-of-care regimen rather than a single novel drug entity.","oneSentence":"Conventional best asthma therapy typically combines inhaled corticosteroids with long-acting beta-2 agonists to reduce airway inflammation and improve bronchodilation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:31:13.926Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Persistent asthma (mild, moderate, or severe)"},{"name":"Asthma maintenance and prevention of exacerbations"}]},"trialDetails":[{"nctId":"NCT04132778","phase":"NA","title":"Digital Prevention of Asthma","status":"TERMINATED","sponsor":"Karolinska Institutet","startDate":"2019-10-14","conditions":"Asthma, Care Management, Patient","enrollment":331},{"nctId":"NCT00628758","phase":"PHASE3","title":"A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-12","conditions":"Asthma","enrollment":430},{"nctId":"NCT00290264","phase":"PHASE3","title":"SALTO - Symbicort Single Inhaler Therapy Use in Adolescent Adults and Adults With Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00252824","phase":"PHASE3","title":"STYLE - Symbicort Single Inhaler Therapy vs Conventional Therapy in Treatment of Persistent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-07","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00242411","phase":"PHASE4","title":"MONO: Symbicort® Single Inhaler Therapy and Conventional Best Standard Treatment for the Treatment of Persistent Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Asthma","enrollment":1900},{"nctId":"NCT00259792","phase":"PHASE3","title":"SYMPHONIE - A Comparison of Symbicort Single Inhaler and Conventional Best Practice for the Treatment of Persistent Asthma in Adolescents and Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00385593","phase":"PHASE3","title":"Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2006-09","conditions":"Asthma, Bronchial","enrollment":654},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600},{"nctId":"NCT00238784","phase":"PHASE3","title":"SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-05","conditions":"Asthma","enrollment":1300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Conventional Best Asthma Therapy","genericName":"Conventional Best Asthma Therapy","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Conventional best asthma therapy typically combines inhaled corticosteroids with long-acting beta-2 agonists to reduce airway inflammation and improve bronchodilation. Used for Persistent asthma (mild, moderate, or severe), Asthma maintenance and prevention of exacerbations.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}